Radius Health Announces Three Presentations on RAD1901 at the San Antonio Breast Cancer Symposium (SABCS) December 6-10, 2016

On August 30, 2016 Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported that it will present new data from multiple studies of RAD1901, an oral selective estrogen degrader, in ER-positive breast cancer at the San Antonio Breast Cancer Symposium Meeting December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San Antonio, Texas (Press release, Radius, AUG 30, 2016, View Source [SID:1234514796]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the abstracts related to RAD1901 are below:

Abstract Title: A Phase 1 Study of RAD1901, a Novel, Oral, Selective Estrogen Receptor Degrader (SERD), for the Treatment of ER-Positive Advanced Breast Cancer, Poster # 1454
Poster Session 4
Session Title: Treatment: Advanced Endocrine Therapy
Session Date: 12/8/2016
Session Time: 7:30 AM — 9:00 AM
Location: Hall 1

Abstract Title: A Phase 1 Study of RAD1901, an Oral Selective Estrogen Receptor Degrader, to Determine Changes in the F-FES Uptake and Tumor Responses in ER-Positive, HER-2-Negative, Advanced Breast Cancer Patients, Poster # 1604
Poster Session 4
Session Title: Treatment, Advanced Endocrine Therapy
Session Date: 12/8/2016
Session Time: 7:30 AM — 9:00 AM
Location: Hall1

Abstract Title: RAD1901 Demonstrates Anti-Tumor Activity in Multiple Models of ER+ Breast Cancer Treatment Resistance, Poster # 1378
Poster Session 4
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: 12/8/2016
Session Time: 5:00 PM — 7:00 PM
Location: Hall 1